Skip to Content
Merck
CN

HCYTA-60K

MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Panel A

Configurable Human Cytokine/Chemokine/Growth Factor 48-Plex Panel A

Synonym(s):

Human cytokine multiplex kit, Luminex® human cytokine immunoassay, Millipore human cytokine panel

Sign In to View Organizational & Contract Pricing.

About This Item

NACRES:
NA.84
UNSPSC Code:
12161503
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Panel A, Configurable Human Cytokine/Chemokine/Growth Factor 48-Plex Panel A

Quality Level

species reactivity

human

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

technique(s)

multiplexing: suitable

input

cell culture supernatant
serum

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 48 analytes in human serum, plasma, and cell culture supernatants.Analytes included: sCD40L, EGF, Eotaxin/CCL11, FGF-2/FGF-basic, FLT-3L, Fractalkine/CX3CL1, G-CSF, GM-CSF, GROα, IFNα2, IFNγ, IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12(p70), IL-13, IL-15, IL-17A/CTLA8, IL-17E/IL-25, IL-17F, IL-18, IL-22, IL-27, IP-10/CXCL10, MCP-1/CCL2, MCP-3/CCL7, M-CSF, MDC, MIG/CXCL9, MIP-1α/CCL3, MIP-1β/CCL4, PDGF-AA, PDGF-AB/BB, RANTES/CCL5, TGFα, TNFα, TNFβ/LTA, VEGF-ANote: RANTES cannot be plexed with other cytokines in this panel due to a required 1:100 dilution of plasma/serum samples.Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Disclaimer

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Features and Benefits

48-Plex Power, Simplified: One kit unlocks 48 biomarkers—replaces multiple ELISAs and slashes costs.More Than 20-Year Multiplexing Legacy: The original multiplex innovator—trusted by top pharma companies for critical assays.Cancer, Autoimmunity, & Beyond: Power research in immunotherapy, sepsis, Alzheimer′s, and Long COVID biomarker discovery.Intuitive Workflow: User-friendly protocols that require minimal training, allowing researchers to achieve publication-ready results without extensive background in multiplex assays.Configurable Assay Design: Configure your panel by selecting specific analytes based on your research needs, allowing for a tailored approach that maximizes relevance and impact.Robust Sample Compatibility: Verified for serum, plasma, PBMC supernatants, and cell/tissue lysates. Tested across normal and disease-state samples for broad applicability.Peer-Reviewed Credibility: Frequently cited in immunology and clinical research publications. Trusted by academic institutions, CROs, and pharma companies.Performance Highlights from Comparative Studies: MILLIPLEX® assays showed highest reproducibility among Luminex®-based kits in a head-to-head study and in disease profiling (e.g., ovarian cancer, sepsis), and MILLIPLEX® assays detected more significantly elevated analytes than competitors.Global Support & Documentation: Backed by extensive technical documentation, protocols, and customer support.

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

Storage Class

10 - Combustible liquids

Regulatory Information

新产品
This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yiwei Zhao et al.
Fertility and sterility, 115(4), 1044-1053 (2020-12-05)
To compare the changing peripheral levels of inflammation-related cytokine profile during a 9-day period after blastocyst transfer between women who did and did not conceive. Prospective, observational, and longitudinal study. University-affiliated hospital. Forty-seven women with infertility who were undergoing single
Carl A Pierce et al.
JCI insight, 6(9) (2021-04-07)
BACKGROUNDCoronavirus disease 2019 (COVID-19) is more benign in children compared with adults for unknown reasons. This contrasts with other respiratory viruses where disease manifestations are often more severe in children. We hypothesize that a more robust early innate immune response
Manuel Cabeza-Segura et al.
British journal of cancer, 127(12), 2198-2206 (2022-10-18)
Advanced gastro-oesophageal cancer (GEA) treatment has been improved by the introduction of immune checkpoint inhibitors (CPIs), yet identifying predictive biomarkers remains a priority, particularly in patients with a combined positive score (CPS) < 5, where the benefit is less clear. Our study
Carl A Pierce et al.
medRxiv : the preprint server for health sciences (2021-02-18)
COVID-19 is more benign in children compared to adults for unknown reasons. This contrasts with viruses such as influenza where disease manifestations are often more severe in children1. We hypothesized that a more robust early innate immune response to SARS-CoV-2
Vimvara Vacharathit et al.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 112, 227-234 (2021-09-19)
As coronavirus disease 2019 (COVID-19) rages on worldwide, there is an urgent need to characterize immune correlates of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and to identify immune determinants of COVID-19 severity. This study examined the

Related Content

通过适合的免疫检测产品,探索神经免疫和神经炎症细胞因子及神经退行性疾病生物标志物。

Cytokine multiplex assays allow researchers to easily investigate the immune system. The MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Multiplex Panels A and B are multiplex assays for cytokine detection that each offer a unique combination of 48 analytes that can be simultaneously analyzed in a small sample volume.

Immunology multiplex assays, like MILLIPLEX® assays, allow researchers to investigate more immune biomarkers simultaneously, saving time and resources.

Discover the benefits of MILLIPLEX® multiplex assays, based on Luminex® xMAP® multiplex assay technology, that provide consistent, high-quality results and see how these multiplex biomarker Luminex® assays are being used to advance research.

See All

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service